EKR Therapeutics, Inc.'s URGENT Study Provides Important New Insight into the Use of Dyspnea as a Clinical Endpoint for Evaluating New Treatments for Acute Heart Failure Syndromes

BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today said that its prospective, observational study of heart failure patients showed that early evaluation of dyspnea (shortness of breath) is crucial in assessing patients with acute heart failure syndromes (AHFS).